首页|中国地区局限性晚期宫颈癌动脉介入新辅助化疗有效性与安全性:基于随机对照试验的Meta分析与GRADE证据评分

中国地区局限性晚期宫颈癌动脉介入新辅助化疗有效性与安全性:基于随机对照试验的Meta分析与GRADE证据评分

扫码查看
目的 评估新辅助动脉介入化疗(NAIC)和新辅助全身静脉化疗(NIVC)治疗局部晚期宫颈癌(LACC)的有效性与安全性.方法 通过检索PubMed、Web of Science、Embase、中国知网、万方数据库获取符合主题的随机对照试验(RCT),经文献质量评估和数据提取后使用Stata 17.0进行统计学分析,使用GRADE质量评价系统对结局进行质量评估.结果 共纳入14项RCT,合计1 063例LACC患者.Meta分析结果表明,NAIC和NIVC在有效性指标方面:完全缓解(CR)[RR=1.23,95%CI(0.91,1.67),P=0.174]、部分缓解(PR)[RR=1.10,95%CI(0.86,1.20),P=0.874]、总缓解(TR)[RR=1.10,95%CI(0.95,1.25),P=0.212]、无变化(NC)[RR=0.62,95%CI(0.33,1.16),P=0.137]和进展(PD)[RR=1.43,95%CI(0.41,4.99),P=0.574]间的差异无统计学意义;在安全性指标方面:胃肠道反应[RR=0.96,95%CI(0.76,1.23),P=0.755]、肝肾功能损害[RR=0.71,95%CI(0.41,1.23),P=0.226]差异无统计学意义,而在骨髓抑制[RR=0.62,95%CI(0.45,0.86),P=0.04]的发生率方面,NAIC 较 NIVC 更优.此外,GRADE评分结果显示CR、PR、TR、NC为高质量证据.结论 对于LACC患者,NAIC在治疗后骨髓抑制的发生率较NIVC更低、更安全,在其他有效性与安全性指标上两者并未发现显著差异.临床医师根据患者的实际情况综合评估,选择适宜新辅助化疗方案.
Efficacy and safety of arterial interventional neoadjuvant chemotherapy for locally advanced cervical cancer in China:a Meta-analysis of randomized controlled trials and GRADE evidence score
Objective To evaluate the efficacy and safety of neoadjuvant arterial interventional chemotherapy(NAIC)and neoadjuvant intravenous chemotherapy(NIVC)for the treatment of locally advanced cervical cancer(LACC).Methods Randomized controlled trials(RCTs)which fit the theme were included by searching PubMed,Web of Science,Embase,CNKI,and Wanfang databases.After study quality assessment and data extraction,statistical analysis was performed using Stata 17.0,and outcome quality was assessed using the GRADE system.Results A total of 14 RCTs were included,with 1 063 LACC patients.The results of the Meta-analysis showed that NAIC and NIVC had a positive effect on the effectiveness indicators:complete response(CR)[RR=1.23,95%CI(0.91,1.67),P=0.174],partial response(PR)[RR=1.10,95%CI(0.86,1.20),P=0.874],total response(TR)[RR=1.10,95%CI(0.95,1.25),P=0.212],no change(NC)[RR=0.62,95%CI(0.33,1.16),P=0.137]and progressive disease(PD)[RR=1.43,95%CI(0.41,4.99),P=0.574]were not statistically significant.Differences in safety indicators:gastrointestinal reactions[RR=0.96,95%CI(0.76,1.23),P=0.755],hepatic and renal impairment[RR=0.71,95%CI(0.41,1.23),P=0.226]were not statistically significant.While in the incidence of myelosuppression[RR=0.62,95%CI(0.45,0.86),P=0.04],NAIC was superior to NIVC.In addition,the GRADE score results showed CR,PR,TR,and NC were high-quality evidence.Conclusion For LACC patients,the incidence of myelosuppression after treatment with NAIV is lower and safer than that with NIVC,and no significant difference was found between the two in terms of other efficacy and safety indicators.Clinicians should choose the appropriate neoadjuvant chemotherapy regimen based on a comprehensive assessment of the patient's actual condition.

Locally advanced cervical cancerNeoadjuvant chemotherapyArterial interventional chemotherapyIntravenous chemotherapyMeta-analysis

赵丽、彭磊、张少华、杨春艳、左漫云、杨红梅、别俊

展开 >

首都医科大学附属北京安贞医院南充医院肿瘤科(四川南充 637000)

深圳大学附属华南医院马达机器人研究所(广东 深圳 518000)

局部晚期宫颈癌 新辅助化疗 动脉介入化疗 静脉全身化疗 Meta分析

2024

中国药师
国家药品监督管理局高级研修学院,武汉医药(集团)股份有限公司

中国药师

CSTPCD
影响因子:0.944
ISSN:1008-049X
年,卷(期):2024.28(11)